Overview

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).
Phase:
Phase 2
Details
Lead Sponsor:
Lexicon Pharmaceuticals